353 related articles for article (PubMed ID: 24874954)
1. An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Feng Q; Zhang Z; Shea MJ; Creighton CJ; Coarfa C; Hilsenbeck SG; Lanz R; He B; Wang L; Fu X; Nardone A; Song Y; Bradner J; Mitsiades N; Mitsiades CS; Osborne CK; Schiff R; O'Malley BW
Cell Res; 2014 Jul; 24(7):809-19. PubMed ID: 24874954
[TBL] [Abstract][Full Text] [Related]
2. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
3. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
4. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
[TBL] [Abstract][Full Text] [Related]
5. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
[TBL] [Abstract][Full Text] [Related]
6. BETs abet Tam-R in ER-positive breast cancer.
Alluri PG; Asangani IA; Chinnaiyan AM
Cell Res; 2014 Aug; 24(8):899-900. PubMed ID: 25001387
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H
Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
[TBL] [Abstract][Full Text] [Related]
10. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
Bobustuc GC; Smith JS; Maddipatla S; Jeudy S; Limaye A; Isley B; Caparas ML; Constantino SM; Shah N; Baker CH; Srivenugopal KS; Baidas S; Konduri SD
Mol Med; 2012 Sep; 18(1):913-29. PubMed ID: 22549111
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
12. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
[TBL] [Abstract][Full Text] [Related]
14. Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
Traboulsi T; El Ezzy M; Dumeaux V; Audemard E; Mader S
Oncogene; 2019 Feb; 38(7):1019-1037. PubMed ID: 30190545
[TBL] [Abstract][Full Text] [Related]
15. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.
Yoshimaru T; Komatsu M; Matsuo T; Chen YA; Murakami Y; Mizuguchi K; Mizohata E; Inoue T; Akiyama M; Yamaguchi R; Imoto S; Miyano S; Miyoshi Y; Sasa M; Nakamura Y; Katagiri T
Nat Commun; 2013; 4():2443. PubMed ID: 24051437
[TBL] [Abstract][Full Text] [Related]
16. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
17. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
